<p><strong>Hepatic Impairment</strong>: The systemic exposure to axitinib was higher in subjects with moderate hepatic impairment (Child-Pugh class B) compared to subjects with normal hepatic function. A dose decrease is recommended when administering Axitinib to patients with moderate hepatic impairment (Child-Pugh class B). Axitinib has not been studied in patients with severe hepatic impairment (Child-Pugh class C)&nbsp;<br />
<br />
<strong>Renal Impairment</strong>: No dedicated renal impairment trial for axitinib has been conducted. Based on the population pharmacokinetic analyses, no significant difference in axitinib clearance was observed in patients with pre-existing mild to severe renal impairment (15 mL/min &le; ClCr &lt; 89 mL/min). No starting dose adjustment is needed for patients with pre-existing mild to severe renal impairment. Caution should be used in patients with end-stage renal disease (ClCr&lt; 15 mL/min).<br />
<br />
<strong>Pediatric Use</strong>: The safety and efficacy of axitinib in pediatric patients have not been studied.<br />
<br />
<strong>Geriatric Use</strong>:&nbsp;No dosage adjustment is required in elderly patients</p>